GlassScriptPhysician profile
Tyson A Harris
NPI 1588905699
$8,073.81
in general payments reported to CMS, 2019-2025
35 companies · $1,914 in 2025
The $1,914 reported for 2025 was more than what 93% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $849 · 2022: $731 · 2023: $1,407 · 2024: $3,173 · 2025: $1,914.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,075 · Travel and Lodging: $1,419.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,074.64 |
| Travel and Lodging | $1,418.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,878.09 | 2021-2025 | Watchman Flx, Watchman Access System, Farapulse |
| Enterra Medical, INC. | $1,729.65 | 2024 | |
| Abbvie INC. | $1,216.01 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $433.12 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Celgene Corporation | $381.70 | 2021-2024 | Zeposia |
| Pfizer INC. | $362.39 | 2021-2025 | |
| Janssen Biotech, INC. | $336.56 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Phathom Pharmaceuticals, INC. | $189.78 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $185.66 | 2022-2025 | Dupixent |
| Gilead Sciences, INC. | $147.81 | 2023-2025 | |
| Ardelyx, INC. | $130.32 | 2023-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $96.89 | 2021-2025 | Relistor, Trulance |
| Novartis Pharmaceuticals Corporation | $91.48 | 2021-2022 | |
| Qol Medical, LLC | $86.88 | 2024-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $84.35 | 2023-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $80.46 | 2024-2025 | Iqirvo |
| Aimmune Therapeutics, INC. | $71.14 | 2024-2025 | Zenpep, Vowst |
| Madrigal Pharmaceuticals | $65.61 | 2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $63.41 | 2022-2025 | Ocaliva |
| Braintree Laboratories, INC. | $57.25 | 2023-2025 | Suflave |
| Ferring Pharmaceuticals INC. | $53.33 | 2021-2023 | Rebyota |
| Nestle Healthcare Nutrition INC. | $49.09 | 2022-2023 | |
| Echosens North America, INC. | $35.39 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $31.90 | 2021-2022 | |
| Emd Serono, INC. | $31.83 | 2023 | Mavenclad |
| Redhill Biopharma INC. | $22.24 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.25 | 2021 | |
| Merck Sharp & Dohme LLC | $20.92 | 2023 | Dificid |
| Amgen INC. | $20.55 | 2021 | |
| Abbott Laboratories | $19.67 | 2021 | |
| Neurocrine Biosciences, INC. | $19.56 | 2023 | Ingrezza |
| Fresenius Kabi USA, LLC | $16.70 | 2024 | Idacio |
| Convatec INC. | $14.79 | 2023 | |
| Lilly USA, LLC | $14.37 | 2025 | Omvoh |
| Novo Nordisk INC | $13.66 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyson Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.